Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
David Y. Graham, Maria Pina Dore & Hong Lu. (2018) Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Review of Anti-infective Therapy 16:9, pages 679-687.
Read now
Read now
Sotirios D Georgopoulos, Vasilios Papastergiou & Stylianos Karatapanis. (2015) Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opinion on Pharmacotherapy 16:15, pages 2307-2317.
Read now
Read now
Francis Mégraud. (2013) Current recommendations for therapies in a world of evolving resistance. Gut Microbes 4:6, pages 541-548.
Read now
Read now
Javier P. Gisbert, Javier Molina-Infante, Alicia C. Marin, Gemma Vinagre, Jesus Barrio & Adrian Gerald McNicholl. (2013) Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection. Scandinavian Journal of Gastroenterology 48:6, pages 652-656.
Read now
Read now
Alicia C Marin, Adrian G McNicholl & Javier P Gisbert. (2013) A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opinion on Pharmacotherapy 14:7, pages 843-861.
Read now
Read now
Sotirios D Georgopoulos, Vasilios Papastergiou & Stylianos Karatapanis. (2013)
Current options for the treatment of
. Expert Opinion on Pharmacotherapy 14:2, pages 211-223.
Read now
Read now
Wouter J den Hollander & Ernst J Kuipers. (2012) Current pharmacotherapy options for gastritis. Expert Opinion on Pharmacotherapy 13:18, pages 2625-2636.
Read now
Read now
Articles from other publishers (92)
Olga P. Nyssen, Dino Vaira, Ángeles Pérez Aísa, Luis Rodrigo, Manuel Castro-Fernandez, Laimas Jonaitis, Bojan Tepes, Liudmila Vologzhanina, María Caldas, Angel Lanas, Alfredo J. Lucendo, Luis Bujanda, Juan Ortuño, Jesús Barrio, Jose M. Huguet, Irina Voynovan, Jorge Perez Lasala, Aiman Silkanovna Sarsenbaeva, Luis Fernandez-Salazar, Javier Molina-Infante, Natasa Brglez Jurecic, Miguel Areia, Antonio Gasbarrini, Juozas Kupčinskas, Dmitry Bordin, Ricardo Marcos-Pinto, Frode Lerang, Marcis Leja, Gyorgy M. Buzas, Yaron Niv, Theodore Rokkas, Perminder Phull, Sinead Smith, Oleg Shvets, Marino Venerito, Vladimir Milivojevic, Ilkay Simsek, Vincent Lamy, Peter Bytzer, Lyudmila Boyanova, Lumír Kunovský, Christoph Beglinger, Michael Doulberis, Wojciech Marlicz, Adrian Goldis, Ante Tonkić, Lisette Capelle, Ignasi Puig, Francis Megraud, Colm O’ Morain, Javier P. Gisbert, Giulia Fiorinni, Ilaria Maria Saracino, Manuel Pabon Carrasco, Alma Keco Huerga, Enrique Alfaro Almajano, Samuel Jesus Martinez Dominguez, Horacio Alonso Galan, Benito Velayos, Carmen Dueñas Sadornil, Jose Maria Botargues Bote, Pedro Luis Gonzalez-Cordero, Miguel Areia, Blas Jose Gomez Rodriguez, Rinaldo Pellicano, Óscar Nuñez, Francesco Franceschi, Sergey Alekseenko, Monica Perona, Rustam Abdulkhakov, Manuel Dominguez-Cajal, Pedro Almela Notari, Judith Gomez Camarero, Manuel Jimenez Moreno, Alicia Algaba, Fernando Bermejo, Jose Maria Botargues Bote, Javier Tejedor Tejada, Elida Oblitas Susanibar, Doron Boltin, Sotirios Georgopoulos, Colm OMorain, Asghar Qasim, Ian Beales, Natalia Bakulina, Galina Fadeenko, Peter Malfertheiner, Rosa Rosania, Tatiana Ilchishina, Pavel Bogomolov, Igor Bakulin, Oleg Zaytsev, Antonietta Gerarda Gravina, Marco Romano, Alfredo Di Leo, Giuseppe Losurdo, Ludmila Grigorieva, Pedro Delgado Guillena, Marinko Marusic, Dragan Jurcic, Natalia Nikolaevna Dekhnich, Eduardo Iyo, Luisa Carmen de la Peña Negro, Natalia Baryshnikova, Natalia Bakanova, Halis Simsek, Cem Simsek, Oleksiy Gridnyev, Miguel Fernandez-Bermejo, Teresa Angueira, Rafael Ruiz-Zorrilla Lopez, Barbara Gomez, Mila Kovacheva-Slavova, Adi Lahat, Javier Alcedo, Ana Campillo, Liya Nikolaevna Belousova, Ramon Pajares Villarroya, Neven Ljubicic, Marko Nikolic, Jesús M. González-Santiago, Diego Burgos Santamaría, Anna Pakhomova, Izabela Sekulic-Spasic, Matteo Ghisa, Fabio Farinati, Sabir Irfan Sagdati, Nikola Panic, Frederic Heluwaert, Edurne Amorena, Leticia Moreira, Gloria Fernandez Esparrach, Ekaterina Yuryevna Plotnikova, Michal Kukla, Victor Kamburov, Luis Javier Lamuela Calvo, Ivan Rankovic, Antonio Cuadrado Lavín, Yolanda Arguedas Lazaro, Victor Gonzalez Carrera Agnieszka Dobrowolska, Piotr Eder & Alla Kononova. (2022) Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology 20:10, pages 2243-2257.
Crossref
Crossref
Lorena Elena Meliț, Cristina Oana Mărginean & Maria Oana Săsăran. (2022) The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics. Children 9:6, pages 795.
Crossref
Crossref
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo J. Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa & Ignasi Puig. (2022) V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología y Hepatología 45:5, pages 392-417.
Crossref
Crossref
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa & Ignasi Puig. (2022) V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 45:5, pages 392-417.
Crossref
Crossref
Ahmad Alfadhli, Mohamed Alboraie, Mostafa Afifi & Abhijit Dangi. (2022) A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait. Journal of Global Infectious Diseases 14:3, pages 99.
Crossref
Crossref
Chih-An Shih, Chang-Bih Shie & Ping-I Hsu. (2022)
Update on the first-line treatment of
Helicobacter pylori
infection in areas with high and low clarithromycin resistances
. Therapeutic Advances in Gastroenterology 15, pages 175628482211381.
Crossref
Crossref
Nicolás Zuluaga Arbelaez, Elsy Cristina Sierra-Vargas, Luis Gonzalo Guevara-Casallas & Santiago Pérez-Viana. (2021) Estrategias terapéuticas para Helicobacter pylori en Colombia. CES Medicina 35:3, pages 244-256.
Crossref
Crossref
Ioana Alexandra Cardos, Dana Carmen Zaha, Rakesh K. Sindhu & Simona Cavalu. (2021) Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 26:19, pages 6078.
Crossref
Crossref
Evariste Tshibangu-Kabamba & Yoshio Yamaoka. (2021) Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications. Nature Reviews Gastroenterology & Hepatology 18:9, pages 613-629.
Crossref
Crossref
Nikola Perkovic, Antonio Mestrovic, Josko Bozic, Mirela Pavicic Ivelja, Jonatan Vukovic, Goran Kardum, Zeljko Sundov, Marija Tonkic, Zeljko Puljiz, Katarina Vukojevic & Ante Tonkic. (2021) Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. Journal of Personalized Medicine 11:6, pages 534.
Crossref
Crossref
Sung Eun Kim, Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim & Miyoung Choi. (2021) A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 21:1, pages 48-58.
Crossref
Crossref
Tuncer Ozturk, Demet Sengul & Ilker Sengul. (2021)
Helicobacter pylori
and association between its positivity and anatomotopographic settlement in the stomach with the host age range
. Annals of African Medicine 20:1, pages 1.
Crossref
Crossref
Su Young Kim & Jun-Won Chung. (2020) Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics 9:8, pages 436.
Crossref
Crossref
Bernardo Guevara & Asha Gupta Cogdill. (2020) Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Digestive Diseases and Sciences 65:7, pages 1917-1931.
Crossref
Crossref
Ru-Jia Li, Yuan-Yuan Dai, Chun Qin, Xiao-Hua Li, Yan-Chun Qin, Yong Pan, Yong-Yi Huang, Zan-Song Huang & Yan-Qiang Huang. (2020)
Treatment strategies and preventive methods for drug-resistant
Helicobacter pylori
infection
. World Journal of Meta-Analysis 8:2, pages 98-108.
Crossref
Crossref
Ying Zhou, Ziqing Ye, Yuhuan Wang, Ye Zhang, Zifei Tang, Weili Yan, Yuan Jiang & Ying Huang. (2020)
Comparison of four different regimens against
Helicobacter pylori
as a first‐line treatment: A prospective, cross‐sectional, comparative, open trial in Chinese children
. Helicobacter 25:2.
Crossref
Crossref
Jung Uoon Park, Jin Sook Cho, Jong Seok Kim, Hyun Kyu Kim, Young Hee Jo, Md Aziz Abdur Rahman & Young Ik Lee. (2020) Synergistic Effect of Rubus crataegifolius and Ulmus macrocarpa Against Helicobacter pylori Clinical Isolates and Gastritis. Frontiers in Pharmacology 11.
Crossref
Crossref
I. W. FongI. W. Fong. 2020. Current Trends and Concerns in Infectious Diseases. Current Trends and Concerns in Infectious Diseases
81
102
.
Christina Kapizioni, Georgios Koutoufaris, Vasiliki Ntouli, Konstantinos Makris, Konstantia Milioni, Panagiotis Kourkoulis, Panagiotis Giannelis, Aristotelis Mellos, Georgios Michalopoulos, Spyridon Vrakas & Vasileios Xourgias. (2019) Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study. European Journal of Gastroenterology & Hepatology 31:10, pages 1206-1210.
Crossref
Crossref
A M Veliev, I V Maev, D N Andreev, D T Dicheva, A V Zaborovskii, E G Lobanova & L G Bektemirova. (2019) The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease. Terapevticheskii arkhiv 91:8, pages 28-33.
Crossref
Crossref
Mei-Jyh Chen, Chien-Chuan Chen, Yen-Nien Chen, Chieh-Chang Chen, Yu-Jen Fang, Jaw-Town Lin, Ming-Shiang Wu & Jyh-Ming Liou. (2018) Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology 113:10, pages 1444-1457.
Crossref
Crossref
Amin Talebi Bezmin Abadi & Yoshio Yamaoka. (2018) Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 14, pages 111-117.
Crossref
Crossref
F.J. Bosques-Padilla, J.M. Remes-Troche, M.S. González-Huezo, G. Pérez-Pérez, J. Torres-López, J.M. Abdo-Francis, M.V. Bielsa-Fernandez, M. Constanza-Camargo, F. Esquivel-Ayanegui, E. Garza-González, A.I. Hernández-Guerrero, R. Herrera-Goepfert, F.M. Huerta-Iga, Y. Leal-Herrera, A. Lopéz-Colombo, N.X. Ortiz-Olvera, A. Riquelme-Pérez, C.L. Sampieri, L.F. Uscanga-Domínguez & J.A. Velarde-Ruiz Velasco. (2018) The fourth Mexican consensus on Helicobacter pylori. Revista de Gastroenterología de México (English Edition) 83:3, pages 325-341.
Crossref
Crossref
F.J. Bosques-Padilla, J.M. Remes-Troche, M.S. González-Huezo, G. Pérez-Pérez, J. Torres-López, J.M. Abdo-Francis, M.V. Bielsa-Fernandez, M.C. Camargo, F. Esquivel-Ayanegui, E. Garza-González, A.I. Hernández-Guerrero, R. Herrera-Goepfert, F.M. Huerta-Iga, Y. Leal-Herrera, A. Lopéz-Colombo, N.X. Ortiz-Olvera, A. Riquelme-Pérez, C.L. Sampieri, L.F. Uscanga-Domínguez & J.A. Velarde-Ruiz Velasco. (2018) IV consenso mexicano sobre Helicobacter pylori. Revista de Gastroenterología de México 83:3, pages 325-341.
Crossref
Crossref
Xavier Calvet. (2018)
Dealing with uncertainty in the treatment of
Helicobacter pylori
. Therapeutic Advances in Chronic Disease 9:4, pages 93-102.
Crossref
Crossref
Jung Wan Choe, Sung Woo Jung, Seung Young Kim, Jong Jin Hyun, Young Kul Jung, Ja Seol Koo, Hyung Joon Yim & Sang Woo Lee. (2018)
Comparative study of
Helicobacter pylori
eradication rates of concomitant therapy vs modified quadruple therapy comprising proton‐pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea
. Helicobacter 23:2, pages e12466.
Crossref
Crossref
Yee Hui Yeo, Sz-Iuan Shiu, Hsiu J Ho, Biyao Zou, Jaw-Town Lin, Ming-Shiang Wu, Jyh-Ming Liou & Chun-Ying Wu. (2018)
First-line
Helicobacter pylori
eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis
. Gut 67:1, pages 20-27.
Crossref
Crossref
Kamila Goderska, Sonia Agudo Pena & Teresa Alarcon. (2017) Helicobacter pylori treatment: antibiotics or probiotics. Applied Microbiology and Biotechnology 102:1, pages 1-7.
Crossref
Crossref
Fernando Macías-García, José Llovo-Taboada, Mario Díaz-López, Iria Bastón-Rey & Juan Enrique Domínguez-Muñoz. (2017)
High primary antibiotic resistance of
Helicobacter Pylori
strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain
. Helicobacter 22:6, pages e12440.
Crossref
Crossref
Hafez Fakheri, Mehdi Saberi Firoozi & Zohreh Bari. (2017) Eradication of Helicobacter Pylori in Iran: A Review. Middle East Journal of Digestive Diseases 10:1, pages 5-17.
Crossref
Crossref
Zi-Juan Wang, Xiao-Feng Chen, Zi-Xiao Zhang, Yu-Chen Li, Juan Deng, Jing Tu, Zhi-Qiang Song & Qing-Hua Zou. (2017) Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microbial Pathogenesis 109, pages 156-161.
Crossref
Crossref
Bor-Shyang Sheu, Ming-Shiang Wu, Cheng-Tang Chiu, Jing-Chuan Lo, Deng-Chyang Wu, Jyh-Ming Liou, Chun-Ying Wu, Hsiu-Chi Cheng, Yi-Chia Lee, Ping-I Hsu, Chun-Chao Chang, Wei-Lun Chang & Jaw-Town Lin. (2017)
Consensus on the clinical management, screening-to-treat, and surveillance of
Helicobacter pylori
infection to improve gastric cancer control on a nationwide scale
. Helicobacter 22:3, pages e12368.
Crossref
Crossref
Stanisław Ferenc, Jan Gnus, Magdalena Kościelna, Małgorzata Kinda, Andriy Yarka, Luke Stewart & Wojciech Witkiewicz. (2017)
High antibiotic resistance of
Helicobacter pylori
and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland
. Helicobacter 22:2, pages e12365.
Crossref
Crossref
William D Chey, Grigorios I Leontiadis, Colin W Howden & Steven F Moss. (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology 112:2, pages 212-239.
Crossref
Crossref
Chih-Ming Liang, Chien-Hua Chiu, Hsing-Ming Wang, Wei-Chen Tai, Chih-Chien Yao, Cheng-En Tsai, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Chen-Hsiang Lee, Kai-Lung Tsai, Chih-Fang Huang & Seng-Kee Chuah. (2017)
First-Line
Helicobacter pylori
Eradication in Patients with Chronic Kidney Diseases in Taiwan
. BioMed Research International 2017, pages 1-7.
Crossref
Crossref
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano & E M El-Omar. (2017)
Management of
Helicobacter pylori
infection—the Maastricht V/Florence Consensus Report
. Gut 66:1, pages 6-30.
Crossref
Crossref
Yiqiao Xin, Jan Manson, Lindsay Govan, Robin Harbour, Jenny Bennison, Eleanor Watson & Olivia Wu. (2016) Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterology 16:1.
Crossref
Crossref
Jyh-Ming Liou, Ming-Shiang Wu & Jaw-Town Lin. (2016)
Treatment of
Helicobacter pylori
infection: Where are we now?
. Journal of Gastroenterology and Hepatology 31:12, pages 1918-1926.
Crossref
Crossref
Javier P. Gisbert, Javier Molina-Infante, Javier Amador, Fernando Bermejo, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Antonio Cuadrado-Lavín, J. Ignasi Elizalde, Emili Gene, Fernando Gomollón, Ángel Lanas, Carlos Martín de Argila, Fermín Mearin, Miguel Montoro, Ángeles Pérez-Aisa, Emilio Pérez-Trallero & Adrián G. McNicholl. (2016) IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología y Hepatología 39:10, pages 697-721.
Crossref
Crossref
Javier P. Gisbert, Javier Molina-Infante, Javier Amador, Fernando Bermejo, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Antonio Cuadrado-Lavín, J. Ignasi Elizalde, Emili Gene, Fernando Gomollón, Ángel Lanas, Carlos Martín de Argila, Fermín Mearin, Miguel Montoro, Ángeles Pérez-Aisa, Emilio Pérez-Trallero & Adrián G. McNicholl. (2016) IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 39:10, pages 697-721.
Crossref
Crossref
Xiuhong Yang, Pengsheng Tan, Lianying Song & Zhanying Lu. (2016) Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. American Journal of Therapeutics 23:6, pages e1436-e1441.
Crossref
Crossref
Adrian G. McNicholl, A. Salvador Pena & Javier P. Gisbert. (2016) Ensuring the highest eradication rates in H. pylori: the case of non-bismuth quadruple concomitant therapy. European Journal of Internal Medicine 33, pages 1-2.
Crossref
Crossref
Sotirios D. Georgopoulos, Elias Xirouchakis, Beatrice Martinez-Gonzales, Evanthia Zampeli, Elias Grivas, Charikleia Spiliadi, Maria Sotiropoulou, Kalliopi Petraki, Kostantinos Zografos, Fotini Laoudi, Dionysios Sgouras, Andreas Mentis, Panagiotis Kasapidis & Spyros Michopoulos. (2016) Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. European Journal of Internal Medicine 32, pages 84-90.
Crossref
Crossref
Elizabeth A. Marcus, George Sachs & David R. Scott. (2016) Eradication of Helicobacter pylori Infection. Current Gastroenterology Reports 18:7.
Crossref
Crossref
Olga P Nyssen, Adrian G McNicholl, Francis Megraud, Vincenzo Savarino, Giuseppina Oderda, Carlo A Fallone, Lori Fischbach, Franco Bazzoli & Javier P Gisbert. (2016)
Sequential versus standard triple first-line therapy for
Helicobacter pylori
eradication
. Cochrane Database of Systematic Reviews 2016:6.
Crossref
Crossref
Christine S. M. Lau, Amanda Ward & Ronald S. Chamberlain. (2015)
Sequential (as Opposed to Simultaneous) Antibiotic Therapy Improves
Helicobacter pylori
Eradication in the Pediatric Population
. Clinical Pediatrics 55:7, pages 614-625.
Crossref
Crossref
Bojan Tepeš, Miroslav Vujasinović, Maja Šeruga, Milan Stefanovič, Alenka Forte & Samo Jeverica. (2016) Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. European Journal of Gastroenterology & Hepatology 28:6, pages 676-683.
Crossref
Crossref
Rute M. Cerqueira, Manuel R. Correia, Hélder Vilar & M. Conceição Manso. (2015) How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?. Obesity Surgery 26:6, pages 1163-1166.
Crossref
Crossref
Saman Alhooei, Hafez Tirgar Fakheri, Vahid Hosseini, Iradj Maleki, Tarang Taghvaei, Seyed Mohammad Valizadeh & Zohreh Bari. (2016) A Comparison between Hybrid and Concomitant Regimens for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 8:3, pages 219-225.
Crossref
Crossref
Liya Zhou, Jianzhong Zhang, Zhiqiang Song, Lihua He, Yanqing Li, Jiaming Qian, Peng Bai, Yan Xue, Ye Wang & Sanren Lin. (2016)
Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial
Helicobacter pylori
Treatment: A Randomized Trial
. Helicobacter 21:2, pages 91-99.
Crossref
Crossref
Angel Cosme, Jacobo Lizasoan, Milagrosa Montes, Esther Tamayo, Horacio Alonso, Usua Mendarte, Maider Martos, María Fernández-Reyes, Cristina Saraqueta & Luis Bujanda. (2016)
Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of
Helicobacter pylori
in a Region with High Rate of Clarithromycin Resistance
. Helicobacter 21:1, pages 29-34.
Crossref
Crossref
Maliheh Safavi. (2016)
Treatment of
Helicobacter pylori
infection: Current and future insights
. World Journal of Clinical Cases 4:1, pages 5.
Crossref
Crossref
Ju Yup Lee & Kyung Sik Park. (2016)
Optimal First-Line Treatment for
Helicobacter pylori
Infection: Recent Strategies
. Gastroenterology Research and Practice 2016, pages 1-7.
Crossref
Crossref
Hyuk Yoon. 2016. Helicobacter pylori. Helicobacter pylori
453
457
.
Muhammad Miftahussurur & Yoshio Yamaoka. 2016. Helicobacter pylori Research. Helicobacter pylori Research
519
542
.
Javier Molina-Infante & David Y. Graham. 2016. Helicobacter pylori Research. Helicobacter pylori Research
471
490
.
Javier Molina-Infante. 2016. Helicobacter pylori. Helicobacter pylori
237
252
.
Sinéad Marian Smith. (2015) An Update on the Treatment of Helicobacter Pylori Infection. EMJ Gastroenterology, pages 101-107.
Crossref
Crossref
Richard J.M. Ingram, Krish Ragunath & John C. Atherton. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
1032
1077
.
Javier Molina-Infante & Akiko Shiotani. (2015) Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterology Clinics of North America 44:3, pages 519-535.
Crossref
Crossref
Jae Kyu Sung. (2015) Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection. The Korean Journal of Medicine 89:2, pages 149-156.
Crossref
Crossref
Antonio Cuadrado-Lavín, J. Ramón Salcines-Caviedes, Ainhoa Diaz-Perez, Miguel F. Carrascosa, María Ochagavía, José Luis Fernandez-Forcelledo, Marta Cobo, Pedro Fernández-Gil, Blanca Ayestarán, Blanca Sánchez, Cristina Campo, Javier Llorca, Silvia Lorenzo & Aitziber Illaro. (2015)
First-line eradication rates comparing two shortened non-bismuth quadruple regimens against
Helicobacter pylori
: an open-label, randomized, multicentre clinical trial
. Journal of Antimicrobial Chemotherapy 70:8, pages 2376-2381.
Crossref
Crossref
Muhammad Miftahussurur & Yoshio Yamaoka. (2015) Appropriate First-Line Regimens to Combat Helicobacter pylori Antibiotic Resistance: An Asian Perspective. Molecules 20:4, pages 6068-6092.
Crossref
Crossref
Ben Wang, You-Hua Wang, Zhi-Fa Lv, Hui-Fang Xiong, Hui Wang, Yang Yang & Yong Xie. (2015)
Review: Efficacy and Safety of Hybrid Therapy for
Helicobacter pylori
Infection: A Systematic Review and Meta-analysis
. Helicobacter 20:2, pages 79-88.
Crossref
Crossref
J. P. Gisbert, M. Romano, A. G. Gravina, P. Solís-Muñoz, F. Bermejo, J. Molina-Infante, M. Castro-Fernández, J. Ortuño, A. J. Lucendo, M. Herranz, I. Modolell, F. del Castillo, J. Gómez, J. Barrio, B. Velayos, B. Gómez, J. L. Domínguez, A. Miranda, M. Martorano, A. Algaba, M. Pabón, T. Angueira, L. Fernández-Salazar, A. Federico, A. C. Marín & A. G. McNicholl. (2015)
Helicobacter pylori
second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments
. Alimentary Pharmacology & Therapeutics 41:8, pages 768-775.
Crossref
Crossref
J. Molina-Infante, A. J. Lucendo, T. Angueira, M. Rodriguez-Tellez, A. Perez-Aisa, A. Balboa, J. Barrio, E. Martin-Noguerol, B. J. Gomez-Rodriguez, J. M. Botargues-Bote, J. Gomez-Camarero, A. Huerta, I. Modolell, I. Ariño, M. T. Herranz-Bachiller, F. Bermejo, A. G. McNicholl, C. O'Morain & J. P. Gisbert. (2015)
Optimised empiric triple and concomitant therapy for
Helicobacter pylori
eradication in clinical practice: the OPTRICON study
. Alimentary Pharmacology & Therapeutics 41:6, pages 581-589.
Crossref
Crossref
Javier P. Gisbert, Marco Romano, Javier Molina-Infante, Alfredo J. Lucendo, Enrique Medina, Inés Modolell, Manuel Rodríguez-Tellez, Blas Gomez, Jesús Barrio, Monica Perona, Juan Ortuño, Inés Ariño, Juan Enrique Domínguez-Muñoz, Ángeles Perez-Aisa, Fernando Bermejo, Jose Luis Domínguez, Pedro Almela, Judith Gomez-Camarero, Judith Millastre, Elisa Martin-Noguerol, Antonietta G. Gravina, Marco Martorano, Agnese Miranda, Alessandro Federico, Miguel Fernandez-Bermejo, Teresa Angueira, Luis Ferrer-Barcelo, Nuria Fernández, Alicia C. Marín & Adrián G. McNicholl. (2015) Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Digestive and Liver Disease 47:2, pages 108-113.
Crossref
Crossref
Su Young Kim. (2015)
Antibiotic treatment for
Helicobacter pylori
: Is the end coming?
. World Journal of Gastrointestinal Pharmacology and Therapeutics 6:4, pages 183.
Crossref
Crossref
Yue-Xi Zhang. (2015)
Primary antibiotic resistance of
Helicobacter pylori
strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study
. World Journal of Gastroenterology 21:9, pages 2786.
Crossref
Crossref
Sang Wook Lee, Hyun Jung Kim & Jae Gyu Kim. (2015)
Treatment of
Helicobacter pylori
Infection in Korea: A Systematic Review and Meta-analysis
. Journal of Korean Medical Science 30:8, pages 1001.
Crossref
Crossref
Lei He, Tao Deng & Hesheng Luo. (2015) Meta-Analysis of Sequential, Concomitant and Hybrid Therapy for <i>Helicobacter pylori</i> Eradication. Internal Medicine 54:7, pages 703-710.
Crossref
Crossref
Guang-Hong Jheng, I-Chen Wu, Hsiang-Yao Shih, Meng-Chieh Wu, Fu-Chen Kuo, Huang-Ming Hu, Chung-Jung Liu, Wen-Hung Hsu, Chi-Tan Hu, Ming-Jong Bair, Chao-Hung Kuo, Deng-Chyang Wu & Ping-I Hsu. (2015)
Comparison of Second-Line Quadruple Therapies with or without Bismuth for
Helicobacter pylori
Infection
. BioMed Research International 2015, pages 1-6.
Crossref
Crossref
Zhiqiang Song, Jianzhong Zhang, Lihua He, Minhu Chen, Xiaohua Hou, Zhaoshen Li & Liya Zhou. (2014) Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Digestive and Liver Disease 46:12, pages 1077-1081.
Crossref
Crossref
Jason Ferreira & Steven F. Moss. (2014) Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection. Current Treatment Options in Gastroenterology 12:4, pages 373-384.
Crossref
Crossref
Kevin S H Liu, Ivan F N Hung, W K Walter Seto, Teresa Tong, Axel S J Hsu, Frank Y F Lam, David Y K But, S Y Wong & Wai K Leung. (2014)
Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for
Helicobacter pylori
in Chinese patients: an open label, randomised, crossover trial
. Gut 63:9, pages 1410-1415.
Crossref
Crossref
Sinéad M. Smith, Rana B. Haider, Humphrey O’Connor, Deirdre McNamara & Colm O’Morain. (2014) Practical treatment of Helicobacter pylori. European Journal of Gastroenterology & Hepatology 26:8, pages 819-825.
Crossref
Crossref
Vincenzo De Francesco, Cesare Hassan, Lorenzo Ridola, Floriana Giorgio, Enzo Ierardi & Angelo Zullo. (2014) Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. Journal of Medical Microbiology 63:5, pages 748-752.
Crossref
Crossref
Adrian G McNicholl, Alicia C Marin, Javier Molina-Infante, Manuel Castro, Jesús Barrio, Julio Ducons, Xavier Calvet, Cristobal de la Coba, Miguel Montoro, Felipe Bory, Angeles Perez-Aisa, Montserrat Forné & Javier P Gisbert. (2014)
Randomised clinical trial comparing sequential and concomitant therapies for
Helicobacter pylori
eradication in routine clinical practice
. Gut 63:2, pages 244-249.
Crossref
Crossref
Hafez Fakheri. (2014)
Helicobacter pylori
eradication in West Asia: A review
. World Journal of Gastroenterology 20:30, pages 10355.
Crossref
Crossref
Javier Molina-Infante. (2014)
Optimizing clarithromycin-containing therapy for
Helicobacter pylori
in the era of antibiotic resistance
. World Journal of Gastroenterology 20:30, pages 10338.
Crossref
Crossref
Vasilios Papastergiou. (2014)
Treatment of
Helicobacter pylori
infection: Meeting the challenge of antimicrobial resistance
. World Journal of Gastroenterology 20:29, pages 9898.
Crossref
Crossref
Angelo Zullo, Giuseppe Scaccianoce, Vincenzo De Francesco, Valentina Ruggiero, Pasquale D’Ambrosio, Luigi Castorani, Leonilde Bonfrate, Lucy Vannella, Cesare Hassan & Piero Portincasa. (2013) Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study. Clinics and Research in Hepatology and Gastroenterology 37:6, pages 647-650.
Crossref
Crossref
Javier P. Gisbert. (2013) Enfermedades relacionadas con la infección por Helicobacter pylori. Gastroenterología y Hepatología 36, pages 39-50.
Crossref
Crossref
Anthony O'Connor, Javier Molina-Infante, Javier P. Gisbert & Colm O'Morain. (2013)
Treatment of
Helicobacter pylori
Infection 2013
. Helicobacter 18, pages 58-65.
Crossref
Crossref
Javier Molina–Infante, Marco Romano, Miguel Fernandez–Bermejo, Alessandro Federico, Antonietta G. Gravina, Liliana Pozzati, Elena Garcia–Abadia, Gema Vinagre–Rodriguez, Carmen Martinez–Alcala, Moises Hernandez–Alonso, Agnese Miranda, Maria Rosaria Iovene, Carmen Pazos–Pacheco & Javier P. Gisbert. (2013) Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology 145:1, pages 121-128.e1.
Crossref
Crossref
Nimish Vakil & Dino Vaira. (2013) Treatment for H. pylori Infection. Journal of Clinical Gastroenterology 47:5, pages 383-388.
Crossref
Crossref
Javier P. Gisbert, Xavier Calvet, Fernando Bermejo, Daniel Boixeda, Felipe Bory, Luis Bujanda, Manuel Castro-Fernández, Enrique Dominguez-Muñoz, Juan Ignasi Elizalde, Montserrat Forné, Emili Gené, Fernando Gomollón, Ángel Lanas, Carlos Martín de Argila, Adrián G. McNicholl, Fermín Mearin, Javier Molina-Infante, Miguel Montoro, José María Pajares, Angeles Pérez-Aisa, Emilio Pérez-Trallero & Jordi Sánchez-Delgado. (2013) III Conferencia Española de Consenso sobre la infección por Helicobacter pylori. Gastroenterología y Hepatología 36:5, pages 340-374.
Crossref
Crossref
Giulia Fiorini, Angelo Zullo, Valentina Castelli, Chiara Ricci, Giovanna Lo Re, Ilaria Saracino, Cristina Zaccaro, Federico Maria Verardi, Alessandra Reggi & Dino Vaira. (2013) Therapy for <i>H.</i> <i>pylori</i>: Current concepts. Open Journal of Gastroenterology 03:01, pages 38-41.
Crossref
Crossref
E. M. F. Muri & T. G. Barros. 2013. Hydroxamic Acids. Hydroxamic Acids
241
253
.
Bojan Tepes, Anthony O'Connor, Javier P. Gisbert & Colm O'Morain. (2012) Treatment of Helicobacter pylori infection 2012. Helicobacter 17, pages 36-42.
Crossref
Crossref
Javier P. Gisbert. (2012) Enfermedades relacionadas con la infección por Helicobacter pylori. Gastroenterología y Hepatología 35, pages 12-25.
Crossref
Crossref
Yasser Abu-Safieh & Hanin Yamin. (2012) Sequential and concomitant non-bismuth quadruple therapies are ineffective for <i>H. pylori</i> eradication in Palestine. A randomized trial. Open Journal of Gastroenterology 02:04, pages 177-180.
Crossref
Crossref